Amaral Leonard, Martins Ana, Spengler Gabriella, Hunyadi Attila, Molnar Joseph
Travel Medicine, Centro de Malária Doenças Tropicais, Institute of Hygiene and Tropical Medicine, Universidade Nova de Lisboa, Rua Junqueira 100, 1349-008 Lisbon, Portugal.
Recent Pat Antiinfect Drug Discov. 2013 Dec;8(3):206-12. doi: 10.2174/1574891x08666131210141521.
At this moment, over half million patients suffer from multi-drug resistant tuberculosis (MDR-TB) according to the data from the WHO. A large majority is terminally ill with essentially incurable pulmonary tuberculosis. This herein mini-review provides the experimental and observational evidence that a specific phenothiazine, thioridazine, will contribute to cure any form of drug-resistant tuberculosis. This antipsychotic agent is no longer under patent protection for its initial use. The reader is informed on the recent developments in patenting this compound for "new use" with a special emphasis on the aspects of drug-resistance. Given that economic motivation can stimulate the use of this drug as an antitubercular agent, future prospects are also discussed.
根据世界卫生组织的数据，目前有超过50万患者患有耐多药结核病（MDR-TB）。其中绝大多数患者患有晚期、基本无法治愈的肺结核。本综述提供了实验和观察证据，表明一种特定的吩噻嗪类药物——硫利达嗪，将有助于治愈任何形式的耐药结核病。这种抗精神病药物最初用途的专利保护已过期。本文向读者介绍了该化合物“新用途”专利的最新进展，特别强调了耐药性方面。鉴于经济动机可以刺激该药物作为抗结核药物的使用，本文还讨论了其未来前景。
